A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Stopped The accrual goal could not be met and the drug manufacturer pulled support

Conditions

• Pancreatic Cancer

Interventions

• DRUG: Nivolumab
• DRUG: Nab-Paclitaxel
• DRUG: Gemcitabine
• DRUG: Paricalcitol

Sponsor

Abramson Cancer Center at Penn Medicine